Guangzhou Innogen Pharmaceutical Group Co (HKSE:02591) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:02591 Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
8 GF Score
Price HK$3.60
! 3 Warning Signs
View Full Analysis

What is Guangzhou Innogen Pharmaceutical Group Co Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

HKSE:02591
8GF Score
Guangzhou Innogen Pharmaceutical Group Co Ltd HKSE:02591
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Guangzhou Innogen Pharmaceutical Group Co Business Description

Address No. 2 Tengfei Second Street, Room 409, Building H Self-numbered Creative Building, China-Singapore Guangzhou Knowledge City, Huangpu District, Guangdong Province, Guangzhou, CHN
Guangzhou Innogen Pharmaceutical Group Co Ltd is a company in Asia to commercialize, a humanized, long-acting glucagon-like peptide-1 (GLP-1) receptor agonist. It has commercialized Efsubaglutide Alfa (brand name: Diabegone), its Core Product, for the treatment of type 2 diabetes (T2D) in China. Its core business model is to discover, develop and commercialize therapies for diabetes and other metabolic diseases. The company has built a pipeline of drug candidates namely YN014, YN401, YN209, YN202,YN203 targeting diabetes and other metabolic diseases.
8GF Score

Get the complete analysis for HKSE:02591

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$3.60
Price